Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 September 2003 | Volume 139 Issue 5 Part 1 | Pages 346-351
Background: The development of antibodies to thyroid peroxidase, thyroglobulin, and thyroid-stimulating hormone (TSH) receptor is a main feature of autoimmune thyroid diseases.
Objective: To investigate whether complete removal of thyroid antigens results in the abatement of humoral thyroid autoimmunity.
Design: Retrospective chart review study of patients treated and monitored with a standard prospective protocol.
Setting: University hospital in Pisa, Italy, between 1976 and 1994.
Patients: 182 patients with differentiated thyroid carcinoma and serum antibodies to thyroid peroxidase, thyroglobulin, or TSH receptor due to coexistent clinical Hashimoto thyroiditis, Graves disease, or focal autoimmune thyroiditis.
Intervention: Total thyroidectomy and radioiodine treatment to ablate residual or metastatic thyroid tissue. Regular follow-up with iodine-131 whole-body scanning and serum thyroglobulin measurement. Mean follow-up (±SD) was 10.1 ± 4.1 years (range, 4 to 20 years).
Measurements: Serum antibodies to thyroid peroxidase, thyroglobulin, and TSH receptor.
Results: Thyroid peroxidase, thyroglobulin, and TSH-receptor antibodies progressively disappeared after the initial treatment. The median disappearance time was 6.3 years for thyroid peroxidase antibodies and 3.0 years for thyroglobulin antibodies. There was a statistically significant correlation between the disappearance of thyroid tissue and that of thyroid antibodies. The coexistence of Hashimoto thyroiditis or Graves disease with thyroid cancer did not modify the pattern of disappearance of thyroid antibody compared with patients with focal autoimmune thyroiditis.
Conclusions: Complete ablation of thyroid tissue with its antigenic components results in the disappearance of antibodies to all major thyroid antigens, thus supporting the concept that continued antibody production depends on the persistence of autoantigen in the body.
Editors' Notes
Context
Contribution
Implications
The Editors
Author and Article Information
From Università di Pisa, Pisa, Italy; and Boston University School of Medicine, Boston, Massachusetts.
Drs. Chiovato and Latrofa contributed equally to this paper.
Grant Support: By the University of Pisa (Fondi d'Ateneo) and from the Ministero d'struzione, d'niversità e della Ricerca (MIUR), Rome, Italy.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Aldo Pinchera, MD, Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, Università di Pisa, Ospedale di Cisanello, Via Paradisa 2, 56124 Pisa, Italy; e-mail, a.pinchera{at}endoc.med.unipi.it.
Current Author Addresses: Dr. Chiovato: Cattedra di Endocrinologia, Università di Pavia, U.O. di Endocrinologia, Fondazione Salvatore Maugeri I.R.C.C.S., Istituto di Pavia, Via Ferrata 8, 27100 Pavia, Italy.
Dr. Latrofa: Autoimmune Disease Unit, Cedars-Sinai Research Institute and University of California, Los Angeles School of Medicine, 8700 Beverly Boulevard, D-3057, Los Angeles, CA 90048.
Dr. Braverman: Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, 88 East Newton Street, Boston University School of Medicine, Boston, MA 02118.
Drs. Pacini, Capezzone, Pinchera, and Grasso: Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, Università di Pisa, Ospedale di Cisanello, Via Paradisa 2, 56124 Pisa, Italy.
Dr. Masserini: Dipartimento di Statistica e Matematica Applicata all'Economia, Università di Pisa, Via Ridolfi 10, 56100 Pisa, Italy.
Author Contributions: Conception and design: L. Chiovato, F. Latrofa, A. Pinchera.
Analysis and interpretation of data: L. Chiovato, F. Latrofa, A. Pinchera.
Drafting of the article: L. Chiovato, F. Latrofa, L.E. Braverman, A. Pinchera.
Critical revision of the article for important intellectual content: L. Chiovato, F. Latrofa, L.E. Braverman, A. Pinchera.
Final approval of the article: L. Chiovato, F. Latrofa, L.E. Braverman, A. Pinchera.
Provision of study materials or patients: L. Chiovato, F. Latrofa, F. Pacini, M. Capezzone, L. Grasso, A. Pinchera.
Statistical expertise: F. Latrofa, M. Capezzone, L. Masserini.
Obtaining of funding: A. Pinchera.
Administrative, technical, or logistic support: M. Capezzone.
Collection and assembly of data: F. Latrofa, M. Capezzone. BRIEF COMMUNICATION
Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens
![]()
![]()
Related articles in Annals:
This article has been cited by other articles:
![]() |
F. Latrofa, D. Ricci, L. Grasso, P. Vitti, L. Masserini, F. Basolo, C. Ugolini, G. Mascia, A. Lucacchini, and A. Pinchera Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 591 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Menconi, M. Marino, A. Pinchera, R. Rocchi, B. Mazzi, M. Nardi, L. Bartalena, and C. Marcocci Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves' Orbitopathy Treated with Intravenous Glucocorticoids J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1653 - 1658. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Salvi, G. Vannucchi, I. Campi, N. Curro, D. Dazzi, S. Simonetta, P. Bonara, S. Rossi, C. Sina, C. Guastella, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study Eur. J. Endocrinol., January 1, 2007; 156(1): 33 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF] |
||||
![]() |
D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Salvi, G. Vannucchi, I. Campi, S. Rossi, P. Bonara, F. Sbrozzi, C. Guastella, S. Avignone, G. Pirola, R. Ratiglia, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol., April 1, 2006; 154(4): 511 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Pacini, M. Schlumberger, C. Harmer, G. G Berg, O. Cohen, L. Duntas, F. Jamar, B. Jarzab, E. Limbert, P. Lind, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur. J. Endocrinol., November 1, 2005; 153(5): 651 - 659. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Gorges, M Maniecki, W Jentzen, S. n-Y. Sheu, K Mann, A Bockisch, and O E Janssen Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy Eur. J. Endocrinol., July 1, 2005; 153(1): 49 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Mazzaferri Empirically Treating High Serum Thyroglobulin Levels J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088. [Full Text] [PDF] |
||||
![]() |
F. Latrofa, M. Phillips, B. Rapoport, and S. M. McLachlan Human Monoclonal Thyroglobulin Autoantibodies: Epitopes and Immunoglobulin Genes J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5116 - 5123. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Spencer Challenges of Serum Thyroglobulin (Tg) Measurement in the Presence of Tg Autoantibodies J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3702 - 3704. [Full Text] [PDF] |
||||